The Atrial Fibrillation Health Literacy Information Technology Trial: Pilot Trial of a Mobile Health App for Atrial Fibrillation

Emily Guhl, Andrew D Althouse, Alexandra M Pusateri, Everlyne Kimani, Michael K Paasche-Orlow, Timothy W Bickmore, Jared W Magnani, Emily Guhl, Andrew D Althouse, Alexandra M Pusateri, Everlyne Kimani, Michael K Paasche-Orlow, Timothy W Bickmore, Jared W Magnani

Abstract

Background: Atrial fibrillation (AF) is a common arrhythmia that adversely affects health-related quality of life (HRQoL). We conducted a pilot trial of individuals with AF using a smartphone to provide a relational agent as well as rhythm monitoring. We employed our pilot to measure acceptability and adherence and to assess its effectiveness in improving HRQoL and adherence.

Objective: This study aims to measure acceptability and adherence and to assess its effectiveness to improve HRQoL and adherence.

Methods: Participants were recruited from ambulatory clinics and randomized to a 30-day intervention or usual care. We collected baseline characteristics and conducted baseline and 30-day assessments of HRQoL using the Atrial Fibrillation Effect on Quality of Life (AFEQT) measure and self-reported adherence to anticoagulation. The intervention consisted of a smartphone-based relational agent, which simulates face-to-face counseling and delivered content on AF education, adherence, and symptom monitoring with prompted rhythm monitoring. We compared differences in AFEQT and adherence at 30 days, adjusted for baseline values. We quantified participants' use and acceptability of the intervention.

Results: A total of 120 participants were recruited and randomized (59 to control and 61 to intervention) to the pilot trial (mean age 72.1 years, SD 9.10; 62/120, 51.7% women). The control group had a 95% follow-up, and the intervention group had a 93% follow-up. The intervention group demonstrated significantly higher improvement in total AFEQT scores (adjusted mean difference 4.5; 95% CI 0.6-8.3; P=.03) and in daily activity (adjusted mean difference 7.1; 95% CI 1.8-12.4; P=.009) compared with the control between baseline and 30 days. The intervention group showed significantly improved self-reported adherence to anticoagulation therapy at 30 days (intervention 3.5%; control 23.2%; adjusted difference 16.6%; 95% CI 2.8%-30.4%; P<.001). Qualitative assessments of acceptability identified that participants found the relational agent useful, informative, and trustworthy.

Conclusions: Individuals randomized to a 30-day smartphone intervention with a relational agent and rhythm monitoring showed significant improvement in HRQoL and adherence. Participants had favorable acceptability of the intervention with both objective use and qualitative assessments of acceptability.

Keywords: atrial fibrillation; health literacy; health-related quality of life; medication adherence; mobile phone.

Conflict of interest statement

Conflicts of Interest: None declared.

©Emily Guhl, Andrew D Althouse, Alexandra M Pusateri, Everlyne Kimani, Michael K Paasche-Orlow, Timothy W Bickmore, Jared W Magnani. Originally published in JMIR Cardio (http://cardio.jmir.org), 04.09.2020.

Figures

Figure 1
Figure 1
Relational agent as presented by a smartphone to individuals randomized to the intervention (left); Kardia app as presented by a smartphone (right).

References

    1. January CT, Wann LS, Alpert JS, Calkins H, Cigarroa JE, Cleveland JC, Conti JB, Ellinor PT, Ezekowitz MD, Field ME, Murray KT, Sacco RL, Stevenson WG, Tchou PJ, Tracy CM, Yancy CW, ACC/AHA Task Force Members 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: executive summary: a report of the American college of cardiology/American heart association task force on practice guidelines and the heart rhythm society. Circulation. 2014 Dec 2;130(23):2071–104. doi: 10.1161/CIR.0000000000000040.
    1. Dudink EA, Erküner O, Berg J, Nieuwlaat R, CB CB, Weijs B, A A, AJ AJ, Breithardt G, Le Heuzey JY, Luermans JG, Crijns HJ. The influence of progression of atrial fibrillation on quality of life: a report from the Euro heart survey. Europace. 2018 Jun 1;20(6):929–34. doi: 10.1093/europace/eux217.
    1. Magnani JW, Mujahid MS, Aronow HD, Cené CW, Dickson VV, Havranek E, Morgenstern LB, Paasche-Orlow MK, Pollak A, Willey JZ, American Heart Association Council on Epidemiology and Prevention; Council on Cardiovascular Disease in the Young; Council on Cardiovascular and Stroke Nursing; Council on Peripheral Vascular Disease; Council on Quality of Care and Outcomes Research;Stroke Council Health literacy and cardiovascular disease: fundamental relevance to primary and secondary prevention: a scientific statement from the American Heart Association. Circulation. 2018 Jul 10;138(2):e48–74. doi: 10.1161/CIR.0000000000000579.
    1. Magnani JW, Schlusser CL, Kimani E, Rollman BL, Paasche-Orlow MK, Bickmore TW. The atrial fibrillation health literacy information technology system: pilot assessment. JMIR Cardio. 2017;1(2):e7. doi: 10.2196/cardio.8543.
    1. Bickmore TW, Silliman RA, Nelson K, Cheng DM, Winter M, Henault L, Paasche-Orlow MK. A randomized controlled trial of an automated exercise coach for older adults. J Am Geriatr Soc. 2013 Oct;61(10):1676–83. doi: 10.1111/jgs.12449.
    1. Utami D, Bickmore TW, Barry B, Paasche-Orlow MK. Health literacy and usability of clinical trial search engines. J Health Commun. 2014;19(Suppl 2):190–204. doi: 10.1080/10810730.2014.938842.
    1. Bickmore TW, Utami D, Matsuyama R, Paasche-Orlow MK. Improving access to online health information with conversational agents: a randomized controlled experiment. J Med Internet Res. 2016 Jan 4;18(1):e1. doi: 10.2196/jmir.5239.
    1. Gwynn KB, Winter MR, Cabral HJ, Wolf MS, Hanchate AD, Henault L, Waite K, Bickmore TW, Paasche-Orlow MK. Racial disparities in patient activation: evaluating the mediating role of health literacy with path analyses. Patient Educ Couns. 2016 Jun;99(6):1033–7. doi: 10.1016/j.pec.2015.12.020.
    1. Zhang Z, Bickmore TW, Paasche-Orlow MK. Perceived organizational affiliation and its effects on patient trust: role modeling with embodied conversational agents. Patient Educ Couns. 2017 Sep;100(9):1730–7. doi: 10.1016/j.pec.2017.03.017.
    1. King AC, Bickmore T, Campero I, Pruitt L, Yin L. Employing virtual advisors in preventive care for underserved communities: results from the COMPASS study. J Health Commun. 2013;18(12):1449–64. doi: 10.1080/10810730.2013.798374.
    1. Bickmore TW, Pfeifer LM, Paasche-Orlow MK. Using computer agents to explain medical documents to patients with low health literacy. Patient Educ Couns. 2009 Jun;75(3):315–20. doi: 10.1016/j.pec.2009.02.007.
    1. Ehrenfeld J, Sandberg W, Kwo J, Bickmore T. Use of a Computer Agent to Explain Anesthesia Concepts to Patients. Relational Agents Group. 2010. [2020-08-12]. .
    1. Halcox JP, Wareham K, Cardew A, Gilmore M, Barry JP, Phillips C, Gravenor MB. Assessment of remote heart rhythm sampling using the Alivecor heart monitor to screen for atrial fibrillation: the REHEARSE-AF study. Circulation. 2017 Nov 7;136(19):1784–94. doi: 10.1161/CIRCULATIONAHA.117.030583.
    1. Baker DW, Williams MV, Parker RM, Gazmararian JA, Nurss J. Development of a brief test to measure functional health literacy. Patient Educ Couns. 1999 Sep;38(1):33–42. doi: 10.1016/s0738-3991(98)00116-5.
    1. Kroenke K, Spitzer RL, Williams JB. The PHQ-9: validity of a brief depression severity measure. J Gen Intern Med. 2001 Sep;16(9):606–13. doi: 10.1046/j.1525-1497.2001.016009606.x.
    1. Spertus J, Dorian P, Bubien R, Lewis S, Godejohn D, Reynolds MR, Lakkireddy DR, Wimmer AP, Bhandari A, Burk C. Development and validation of the atrial fibrillation effect on quality-of-life (AFEQT) questionnaire in patients with atrial fibrillation. Circ Arrhythm Electrophysiol. 2011 Feb;4(1):15–25. doi: 10.1161/CIRCEP.110.958033.
    1. Harris PA, Taylor R, Thielke R, Payne J, Gonzalez N, Conde JG. Research electronic data capture (REDCap)--a metadata-driven methodology and workflow process for providing translational research informatics support. J Biomed Inform. 2009 Apr;42(2):377–81. doi: 10.1016/j.jbi.2008.08.010.
    1. Kotecha D, Ahmed A, Calvert M, Lencioni M, Terwee CB, Lane DA. Patient-reported outcomes for quality of life assessment in atrial fibrillation: a systematic review of measurement properties. PLoS One. 2016;11(11):e0165790. doi: 10.1371/journal.pone.0165790.
    1. Randolph TC, Simon DN, Thomas L, Allen LA, Fonarow GC, Gersh BJ, Kowey PR, Reiffel JA, Naccarelli GV, Chan PS, Spertus JA, Peterson ED, Piccini JP, ORBIT AF Investigators and Patients Patient factors associated with quality of life in atrial fibrillation. Am Heart J. 2016 Dec;182:135–43. doi: 10.1016/j.ahj.2016.08.003.
    1. Harrell Jr FJ, Slaughter J. Biostatistics for Biomedical Research. University School of Medicine Nashville. 2001. [2020-08-12]. .
    1. Kirchhof P, Benussi S, Kotecha D, Ahlsson A, Atar D, Casadei B, Castella M, Diener HC, Heidbuchel H, Hendriks J, Hindricks G, Manolis AS, Oldgren J, Popescu BA, Schotten U, van Putte B, Vardas P, Agewall S, Camm J, Esquivias GB, Budts W, Carerj S, Casselman F, Coca A, de Caterina R, Deftereos S, Dobrev D, Ferro JM, Filippatos G, Fitzsimons D, Gorenek B, Guenoun M, Hohnloser SH, Kolh P, Lip GY, Manolis A, McMurray J, Ponikowski P, Rosenhek R, Ruschitzka F, Savelieva I, Sharma S, Suwalski P, Tamargo JL, Taylor CJ, van Gelder IC, Voors AA, Windecker S, Zamorano JL, Zeppenfeld K. 2016 ESC guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur J Cardiothorac Surg. 2016 Nov;50(5):e1–88. doi: 10.1093/ejcts/ezw313.
    1. Brown JD, Shewale AR, Talbert JC. Adherence to rivaroxaban, dabigatran, and apixaban for stroke prevention in incident, treatment-naïve nonvalvular atrial fibrillation. J Manag Care Spec Pharm. 2016 Nov;22(11):1319–29. doi: 10.18553/jmcp.2016.22.11.1319. doi: 10.18553/jmcp.2016.22.11.1319.
    1. Beyer-Westendorf J, Ehlken B, Evers T. Real-world persistence and adherence to oral anticoagulation for stroke risk reduction in patients with atrial fibrillation. Europace. 2016 Aug;18(8):1150–7. doi: 10.1093/europace/euv421.
    1. Fang MC, Go AS, Chang Y, Borowsky LH, Pomernacki NK, Udaltsova N, Singer DE. Warfarin discontinuation after starting warfarin for atrial fibrillation. Circ Cardiovasc Qual Outcomes. 2010 Nov;3(6):624–31. doi: 10.1161/CIRCOUTCOMES.110.937680.
    1. Dorian P, Burk C, Mullin CM, Bubien R, Godejohn D, Reynolds MR, Lakkireddy DR, Wimmer AP, Bhandari A, Spertus J. Interpreting changes in quality of life in atrial fibrillation: how much change is meaningful? Am Heart J. 2013 Aug;166(2):381–7.e8. doi: 10.1016/j.ahj.2013.04.015.

Source: PubMed

Sponsors et collaborateurs

Les conditions médicales

Interventions en matière de drogue

3
S'abonner